Matt Winton

Played a pivotal role in successful acquisition by BioMarin Pharmaceuticals in July 2025 for $270M, delivering a ~182% premium to shareholders Built and scaled operations across CMC, clinical, medical, IT, and commercial functions; directed enterprise strategy, strengthened investor confidence, cultivated patient and medical community support, enabled global strategic partnerships, and regulatory alignment

Led US Multiple Sclerosis (MS) franchise, overseeing P&L for 5 commercial products (AVONEX, PLEGRIDY, TECFIDERA, VUMERITY, and TYSABRI) Drove strategic direction, operational excellence, and maximized commercial initiatives, fostering collaboration among ~350 team members and internal/external partners Achieved over $3 billion in annual revenue through effective management and innovative strategies

Transformed the US Spinal Muscular Atrophy (SMA) franchise by pivoting strategic direction and fostering a high-performance culture Established innovative external collaborations to enhance growth and market presence of SPINRAZA Oversaw team of ~125 rare disease professionals, managing P&L to achieve peak annual revenue exceeding $950M

Acted as a strategic advisor to the CEO, enhancing executive alignment and decision-making Managed the Office of The CEO and help facilitate Board of Directors meetings to ensure effective governance Managed CEO-sponsored initiatives to accelerate business goals

Led a team of 4 payer and channel marketers to develop and execute value maximizing pricing and access strategies Established reimbursement and patient access strategies for MS and rare disease franchises Collaborated cross-functionally to ensure alignment on marketing initiatives and product launches

Developed payer value propositions and tailored resources for MS therapies, aligning with brand objectives Facilitated training and implementation for account management and field reimbursement teams to enhance market and patient access Led cross-functional team that successfully launched PLEGRIDY, exceeding product-level access goals in 2014 and 2015

Spearheaded management consulting engagements for clients in biotech and pharmaceutical sectors, ensuring high client satisfaction with a score of 9.63/10 Deliverables focused on market assessments, corporate and business development, product launch, and pricing and contracting strategy, across oncology, neurology, hematology, and rare disease therapeutic areas Managed and mentored junior staff, providing guidance and oversight on project deliverables

Provided actionable recommendations and advisory services to life science companies, focusing on due diligence, market segmentation, opportunity assessments and portfolio planning to enhance corporate growth strategies Demonstrated strong analytical skills and ability to integrate data from various sources to solve complex problems